Jan V. L.
- Country
- The Netherlands
- Department
- Klinische Immunologie,
Research Overview
- A Phase 3 Randomized Controlled Trial to Evaluate the Efficacy and Safety of Rilzabrutinib in Adults with Active IgG4-Related Disease
- Evaluation of Filgotinib on Quality of Life, Disease Activity, and Safety in Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease
- Phase 3 Randomized Double-Blind Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease
Data & Insights
Has run more than one trial at 10 of 49 partner sites.
Specializations
Rare Inflammatory Conditions
This investigator specializes in the treatment and research of rare immune-mediated inflammatory diseases, with particular emphasis on IgG4-related disease (IgG4-RD).
- IgG4-Related Disease Management
- Disease Flare Prevention
- Novel Therapeutic Approaches
The research focuses on developing innovative treatment strategies for patients with refractory conditions.
Autoimmune Disorders
The investigator conducts research in multiple autoimmune conditions, including Idiopathic Inflammatory Myopathies (IIM) and Behcet's disease.
- Inflammatory Myopathy Treatment
- Behcet's Disease Management
- Refractory Disease Therapy
Areas of interest include quality of life improvements and disease activity monitoring in autoimmune conditions.
Therapeutic Innovation
The investigator explores the application of JAK-inhibitors and targeted biological therapies in rare inflammatory conditions.
- Advanced Biological Treatments
- Safety Assessment
- Treatment Efficacy Evaluation
Research activities concentrate on evaluating new therapeutic options for patients with treatment-resistant conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.